GR-MD-02 (belapectin), an inhibitor of galectin-3 that reduces liver fibrosis, was evaluated for its safety and efficacy in patients with MASH, liver cirrhosis, and PH [342]. This evidence concerns the gene LGALS3 and Hepatic fibrosis.